English, Article edition: Economic Evaluation of Gemcitabine Alone and in Combination with Cisplatin in the Treatment of Nonsmall Cell Lung Cancer M. Lees; M. Aristides; N. Maniadakis; ...

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/93387
Physical Description
  • article
Language
  • English

Edition details

Title
  • Economic Evaluation of Gemcitabine Alone and in Combination with Cisplatin in the Treatment of Nonsmall Cell Lung Cancer
Author
  • M. Lees
  • M. Aristides
  • N. Maniadakis
  • J. McKendrick
  • N. Botwood
  • D. Stephenson
Physical Description
  • article
Notes
  • Objective: To evaluate the cost effectiveness of gemcitabine in the treatment of nonsmall cell lung cancer (NSCLC). Methods: Gemcitabine was compared with best supportive care and gemcitabine/​cisplatin was compared with three standard chemotherapies and four other novel chemotherapy combinations. Costs and effectiveness measures were based on resource and outcome data from previously reported clinical trials. All direct costs associated with NSCLC treatment were included and adjusted to year 2000 values. Perspective: UK National Health Service. Results: Gemcitabine plus best supportive care was associated with an incremental cost per progression-free life year gained of Lstg 5228 compared with best supportive care alone. In comparison with standard chemotherapies, gemcitabine/​cisplatin was associated with an incremental cost per progression-free life year gained of Lstg 1751 versus etoposide/​cisplatin and cost per 1-year survival gain of Lstg 5681 versus mitomycin/​vinblastine/​platinum. Incremental cost per tumour response was Lstg 2032 relative to etoposide/​cisplatin, Lstg 5169 relative to mitomycin/​ifosfamide/​cisplatin and Lstg 6240 relative to mitomycin/​vinblastine/​platinum. Compared with four novel (newer) combination chemotherapies gemcitabine/​ cisplatin showed cost savings in each case, with the same or better outcome. Thus, gemcitabine/​cisplatin showed improved cost effectiveness and dominance. Sensitivity analyses showed the results were robust to variations to the values of key parameters. Conclusion: Gemcitabine alone or in combination with cisplatin was assessed to be a cost-effective or cost-saving therapy when compared with best supportive care, standard chemotherapy regimens and novel chemotherapy combinations. Chemotherapy regimens containing gemcitabine therefore represent good value for money and efficient use of healthcare resources in the treatment of advanced NSCLC.
  • Antineoplastics, Cisplatin, Cost effectiveness, Gemcitabine, Non small cell lung cancer, Pharmacoeconomics
  • RePEc:wkh:phecon:v:20:y:2002:i:5:p:325-337
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment